Related Experiment Video
Updated: Sep 7, 2025
06:32
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
16.4K
PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma
Jiaqing Yi1, BongWoo Kim1, Xuanming Shi1
1Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas.
Cancer Research
|June 22, 2022
Summary
Polycomb repressor complex 2 (PRC2) heterogeneity drives medulloblastoma growth and drug resistance. Mosaic EED loss in PRC2 enhances tumor growth and oncogene expression, highlighting epigenetic heterogeneity
Area of Science:
- Oncology
- Epigenetics
- Developmental Biology
Background:
- Intratumor epigenetic heterogeneity is a key driver of tumor evolution and drug resistance.
- Medulloblastoma, a common childhood brain tumor, exhibits frequent epigenetic abnormalities.
- SHH medulloblastoma subtype is characterized by sonic hedgehog (SHH) signaling and a cerebellum granule neuron precursor (CGNP) cell-of-origin.
Purpose of the Study:
- To investigate the role of Polycomb Repressor Complex 2 (PRC2) heterogeneity in SHH medulloblastoma.
- To determine the impact of EED (a core PRC2 subunit) levels on medulloblastoma growth and progression.
Main Methods:
- Utilized mouse models of medulloblastoma with complete and mosaic deletion of EED.
- Assessed tumor growth, CGNP maintenance, neural differentiation, and cell death.
- Quantified oncogene expression, including Insulin-like Growth Factor 2 (IGF2).
- Analyzed human medulloblastoma cell lines with varying EED levels.
Main Results:
- Complete EED deletion inhibited medulloblastoma growth by depleting CGNPs.
- Mosaic EED deletion significantly enhanced medulloblastoma growth compared to controls.
- Heterogeneous EED levels led to increased oncogene expression (e.g., IGF2), promoting tumor progression.
- EED-low cells promoted EED-high cell growth via paracrine IGF2 signaling.
Conclusions:
- PRC2 heterogeneity, specifically mosaic EED loss, plays an oncogenic role in medulloblastoma.
- PRC2 heterogeneity promotes tumor growth through intrinsic mechanisms and non-cell autonomous signaling.
- Understanding subclone interactions in epigenetic heterogeneity is crucial for medulloblastoma treatment strategies.
Related Concept Videos
01:20The Retinoblastoma Gene
4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:38The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K